12 news items
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This press release (including any oral
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK
31 May 24
presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda
hukgfggxpwnhp4ys0th7boey
ACIU
TAK
13 May 24
, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding
jrmmicolj 576tiz1itd1369aa48koadt61ozwk3nwc8xsr9bg6fosv1
ACIU
TAK
13 May 24
, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company
0fakb9h2ujblpkiw4e 93bnfvvwbd59
TAK
9 May 24
presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda
5bp8s sjcy71m754j4lexql4wn
TAK
26 Apr 24
this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company
swv52v5kkwxeggl6jeanhv6kgsnja7z0dg4dnnik98dbkvy4l0 2e
TAK
22 Apr 24
. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include
ucpjm7mbck5qbomdqqb78y4z3nsott823lhdam7lx7qax1hg93e5mi
TAK
18 Apr 24
not expect a material impact on the consolidated financial statements as a result of this approval
5hda9sgscg3h76urv5 3c7vhov7bl
TAK
26 Mar 24
presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda
- Prev
- 1
- Next